Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: March 6, 2026, 2:36 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 532612 | NSE: INDOCO

Indoco Remedies Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: March 6, 2026, 2:36 am

Market Cap 1,811 Cr.
Current Price 198
Intrinsic Value₹45.23
High / Low 350/194
Stock P/E
Book Value 106
Dividend Yield0.10 %
ROCE0.49 %
ROE7.02 %
Face Value 2.00
PEG Ratio0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Indoco Remedies Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Indoco Remedies Ltd 1,811 Cr. 198 350/194 1060.10 %0.49 %7.02 % 2.00
Panacea Biotec Ltd 1,964 Cr. 321 582/312 1350.00 %4.57 %4.92 % 1.00
Amrutanjan Health Care Ltd 1,641 Cr. 571 791/54428.4 1180.81 %22.4 %16.5 % 1.00
Solara Active Pharma Sciences Ltd 2,039 Cr. 466 734/440 3470.00 %6.01 %0.05 % 10.0
Kwality Pharmaceuticals Ltd 1,570 Cr. 1,513 1,599/63027.5 2810.00 %18.2 %16.2 % 10.0
Industry Average20,550.65 Cr1,093.6755.34201.810.38%16.35%15.16%6.10

All Competitor Stocks of Indoco Remedies Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 399428426482459450431433411390440485445
Expenses 337363365410397401384392399391422442414
Operating Profit 626561716349484012-1184332
OPM % 16%15%14%15%14%11%11%9%3%-0%4%9%7%
Other Income 0004-622122220-5
Interest 7988101214181618262526
Depreciation 17182021242628292929303232
Profit before tax 3839344623337-5-31-46-37-14-31
Tax % 26%34%29%24%31%33%74%107%-8%-9%-1%-32%-6%
Net Profit 2826243516222-10-28-41-36-9-29
EPS in Rs 3.052.802.653.811.772.460.28-1.04-2.86-4.38-3.88-0.86-3.23

Last Updated: February 5, 2026, 1:09 pm

Below is a detailed analysis of the quarterly data for Indoco Remedies Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:

  • For Sales, as of Dec 2025, the value is 445.00 Cr.. The value appears to be declining and may need further review. It has decreased from 485.00 Cr. (Sep 2025) to 445.00 Cr., marking a decrease of 40.00 Cr..
  • For Expenses, as of Dec 2025, the value is 414.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 442.00 Cr. (Sep 2025) to 414.00 Cr., marking a decrease of 28.00 Cr..
  • For Operating Profit, as of Dec 2025, the value is 32.00 Cr.. The value appears to be declining and may need further review. It has decreased from 43.00 Cr. (Sep 2025) to 32.00 Cr., marking a decrease of 11.00 Cr..
  • For OPM %, as of Dec 2025, the value is 7.00%. The value appears to be declining and may need further review. It has decreased from 9.00% (Sep 2025) to 7.00%, marking a decrease of 2.00%.
  • For Other Income, as of Dec 2025, the value is -5.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.00 Cr. (Sep 2025) to -5.00 Cr., marking a decrease of 5.00 Cr..
  • For Interest, as of Dec 2025, the value is 26.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 25.00 Cr. (Sep 2025) to 26.00 Cr., marking an increase of 1.00 Cr..
  • For Depreciation, as of Dec 2025, the value is 32.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 32.00 Cr..
  • For Profit before tax, as of Dec 2025, the value is -31.00 Cr.. The value appears to be declining and may need further review. It has decreased from -14.00 Cr. (Sep 2025) to -31.00 Cr., marking a decrease of 17.00 Cr..
  • For Tax %, as of Dec 2025, the value is -6.00%. The value appears to be increasing, which may not be favorable. It has increased from -32.00% (Sep 2025) to -6.00%, marking an increase of 26.00%.
  • For Net Profit, as of Dec 2025, the value is -29.00 Cr.. The value appears to be declining and may need further review. It has decreased from -9.00 Cr. (Sep 2025) to -29.00 Cr., marking a decrease of 20.00 Cr..
  • For EPS in Rs, as of Dec 2025, the value is -3.23. The value appears to be declining and may need further review. It has decreased from -0.86 (Sep 2025) to -3.23, marking a decrease of 2.37.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 24, 2026, 1:16 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 7318541,0051,0711,0419681,1071,2421,5411,6691,8171,6651,760
Expenses 6106898349149068929831,0171,2131,3811,5721,5651,669
Operating Profit 1201661711571357712322532828824510091
OPM % 16%19%17%15%13%8%11%18%21%17%13%6%5%
Other Income 2214562321206-1
Interest 1911126242126221425386694
Depreciation 3147616368727173797192114123
Profit before tax 72110999148-929132237193136-74-127
Tax % 20%24%17%15%15%-69%16%30%35%26%29%5%
Net Profit 5883827741-3249315514297-78-116
EPS in Rs 6.298.998.898.364.47-0.312.6210.1016.8015.4410.68-7.99-12.35
Dividend Payout % 22%18%18%19%22%-95%11%15%13%15%14%-2%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)43.10%-1.20%-6.10%-46.75%-107.32%900.00%287.50%66.67%-8.39%-31.69%-180.41%
Change in YoY Net Profit Growth (%)0.00%-44.31%-4.89%-40.66%-60.56%1007.32%-612.50%-220.83%-75.05%-23.30%-148.72%

Indoco Remedies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:7%
5 Years:9%
3 Years:3%
TTM:-8%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:%
TTM:-263%
Stock Price CAGR
10 Years:-2%
5 Years:5%
3 Years:-10%
1 Year:-28%
Return on Equity
10 Years:8%
5 Years:9%
3 Years:5%
Last Year:-7%

Last Updated: September 5, 2025, 7:25 am

Balance Sheet

Last Updated: December 4, 2025, 1:25 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 18181818181818181818181818
Reserves 4395005586336576426617518861,0101,0911,004961
Borrowings 9297140280282296262267257333672994999
Other Liabilities 180230224266281301330279325297363414530
Total Liabilities 7298469411,1971,2381,2581,2721,3151,4861,6582,1452,4302,508
Fixed Assets 3253403744404894685905705556789549971,143
CWIP 446355911361855168122114125321182
Investments 00160000002911
Other Assets 3604434966666136056316778098641,0571,1111,182
Total Assets 7298469411,1971,2381,2581,2721,3151,4861,6582,1452,4302,508

Below is a detailed analysis of the balance sheet data for Indoco Remedies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2025, the value is 18.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 18.00 Cr..
  • For Reserves, as of Sep 2025, the value is 961.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,004.00 Cr. (Mar 2025) to 961.00 Cr., marking a decrease of 43.00 Cr..
  • For Borrowings, as of Sep 2025, the value is 999.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 994.00 Cr. (Mar 2025) to 999.00 Cr., marking an increase of 5.00 Cr..
  • For Other Liabilities, as of Sep 2025, the value is 530.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 414.00 Cr. (Mar 2025) to 530.00 Cr., marking an increase of 116.00 Cr..
  • For Total Liabilities, as of Sep 2025, the value is 2,508.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,430.00 Cr. (Mar 2025) to 2,508.00 Cr., marking an increase of 78.00 Cr..
  • For Fixed Assets, as of Sep 2025, the value is 1,143.00 Cr.. The value appears strong and on an upward trend. It has increased from 997.00 Cr. (Mar 2025) to 1,143.00 Cr., marking an increase of 146.00 Cr..
  • For CWIP, as of Sep 2025, the value is 182.00 Cr.. The value appears to be declining and may need further review. It has decreased from 321.00 Cr. (Mar 2025) to 182.00 Cr., marking a decrease of 139.00 Cr..
  • For Investments, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
  • For Other Assets, as of Sep 2025, the value is 1,182.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,111.00 Cr. (Mar 2025) to 1,182.00 Cr., marking an increase of 71.00 Cr..
  • For Total Assets, as of Sep 2025, the value is 2,508.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,430.00 Cr. (Mar 2025) to 2,508.00 Cr., marking an increase of 78.00 Cr..

However, the Borrowings (999.00 Cr.) are higher than the Reserves (961.00 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 99109112891231321238217417915595
Cash from Investing Activity + -41-88-111-171-135-104-56-67-121-208-432-339
Cash from Financing Activity + -59-20-2132-39-16-64-30-4423280241
Net Cash Flow -11-050-51123-148-74-3

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow28.0069.0031.00-123.00-147.00-219.00-139.00-42.0071.00-45.00-427.00-894.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 696669747374696970778277
Inventory Days 148181174189203209230245248228230307
Days Payable 9514613716615719518311710786100152
Cash Conversion Cycle 1221021059711988116197212219212232
Working Capital Days 444648413821225978826239
ROCE %17%21%17%12%7%1%6%16%23%17%10%-0%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 58.69%58.73%58.75%58.75%58.72%58.76%58.76%58.80%58.90%58.90%58.90%58.90%
FIIs 1.55%1.58%1.59%1.69%1.92%1.48%1.70%1.25%1.24%1.22%1.25%1.10%
DIIs 18.06%17.93%17.79%19.56%19.41%18.67%18.25%18.91%18.75%18.96%18.16%18.15%
Public 21.69%21.75%21.87%20.00%19.92%21.07%21.27%21.02%21.02%20.82%21.60%21.76%
Others 0.00%0.00%0.00%0.00%0.03%0.03%0.03%0.03%0.09%0.09%0.09%0.09%
No. of Shareholders 34,73135,43136,58832,60033,20134,51134,41634,67634,49733,12933,31932,659

Shareholding Pattern Chart

No. of Shareholders

Indoco Remedies Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Quant Small Cap Fund 4,199,230 0.33 91.344,199,2302025-04-22 17:25:310%
DSP Healthcare Fund 3,233,474 2.37 70.332,275,9542025-12-08 05:54:2642.07%
Nippon India Small Cap Fund 2,594,559 0.09 56.432,744,5592025-12-08 05:54:26-5.47%
Franklin India Small Cap Fund 2,025,592 0.35 44.06N/AN/AN/A
Nippon India Pharma Fund 1,834,924 0.51 39.911,834,9242025-04-22 17:25:310%
HDFC Value Fund 1,534,403 0.45 33.37N/AN/AN/A
DSP Multicap Fund 462,465 0.39 10.0660,5582025-12-08 05:54:26663.67%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 2.002.002.002.002.00
Basic EPS (Rs.) -8.4610.5315.4416.8010.10
Diluted EPS (Rs.) -8.4510.5115.4216.8010.10
Cash EPS (Rs.) 3.8920.4923.1025.3718.03
Book Value[Excl.RevalReserv]/Share (Rs.) 110.79120.47111.5898.1783.45
Book Value[Incl.RevalReserv]/Share (Rs.) 110.79120.47111.5898.1783.45
Revenue From Operations / Share (Rs.) 180.48197.14181.07167.20134.73
PBDIT / Share (Rs.) 11.3527.5731.3035.7724.68
PBIT / Share (Rs.) -0.9917.6123.6427.2116.74
PBT / Share (Rs.) -8.0614.7320.9225.6714.32
Net Profit / Share (Rs.) -8.4510.5215.4416.8010.10
NP After MI And SOA / Share (Rs.) -7.9910.6815.4416.8010.10
PBDIT Margin (%) 6.2813.9817.2821.3918.31
PBIT Margin (%) -0.548.9313.0516.2712.42
PBT Margin (%) -4.467.4711.5515.3510.63
Net Profit Margin (%) -4.685.338.5210.047.49
NP After MI And SOA Margin (%) -4.425.418.5210.047.49
Return on Networth / Equity (%) -7.218.8713.8317.1112.09
Return on Capital Employeed (%) -0.5610.5917.6523.6216.98
Return On Assets (%) -3.034.598.5710.417.07
Long Term Debt / Equity (X) 0.520.310.130.100.12
Total Debt / Equity (X) 0.950.590.300.260.27
Asset Turnover Ratio (%) 0.720.951.061.100.95
Current Ratio (X) 1.241.561.901.821.53
Quick Ratio (X) 0.720.981.141.090.94
Inventory Turnover Ratio (X) 4.311.431.291.441.36
Dividend Payout Ratio (NP) (%) -18.7521.0514.578.920.00
Dividend Payout Ratio (CP) (%) 34.4710.899.745.910.00
Earning Retention Ratio (%) 118.7578.9585.4391.080.00
Cash Earning Retention Ratio (%) 65.5389.1190.2694.090.00
Interest Coverage Ratio (X) 1.586.6811.5223.3110.21
Interest Coverage Ratio (Post Tax) (X) -0.193.256.6811.955.18
Enterprise Value (Cr.) 3109.493659.623301.123694.362857.47
EV / Net Operating Revenue (X) 1.872.011.982.402.30
EV / EBITDA (X) 29.7014.4011.4511.2112.57
MarketCap / Net Operating Revenue (X) 1.291.671.802.252.14
Retention Ratios (%) 118.7578.9485.4291.070.00
Price / BV (X) 2.112.732.923.843.46
Price / Net Operating Revenue (X) 1.291.671.802.252.14
EarningsYield -0.030.030.040.040.03

After reviewing the key financial ratios for Indoco Remedies Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
  • For Basic EPS (Rs.), as of Mar 25, the value is -8.46. This value is below the healthy minimum of 5. It has decreased from 10.53 (Mar 24) to -8.46, marking a decrease of 18.99.
  • For Diluted EPS (Rs.), as of Mar 25, the value is -8.45. This value is below the healthy minimum of 5. It has decreased from 10.51 (Mar 24) to -8.45, marking a decrease of 18.96.
  • For Cash EPS (Rs.), as of Mar 25, the value is 3.89. This value is within the healthy range. It has decreased from 20.49 (Mar 24) to 3.89, marking a decrease of 16.60.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 110.79. It has decreased from 120.47 (Mar 24) to 110.79, marking a decrease of 9.68.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 110.79. It has decreased from 120.47 (Mar 24) to 110.79, marking a decrease of 9.68.
  • For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 180.48. It has decreased from 197.14 (Mar 24) to 180.48, marking a decrease of 16.66.
  • For PBDIT / Share (Rs.), as of Mar 25, the value is 11.35. This value is within the healthy range. It has decreased from 27.57 (Mar 24) to 11.35, marking a decrease of 16.22.
  • For PBIT / Share (Rs.), as of Mar 25, the value is -0.99. This value is below the healthy minimum of 0. It has decreased from 17.61 (Mar 24) to -0.99, marking a decrease of 18.60.
  • For PBT / Share (Rs.), as of Mar 25, the value is -8.06. This value is below the healthy minimum of 0. It has decreased from 14.73 (Mar 24) to -8.06, marking a decrease of 22.79.
  • For Net Profit / Share (Rs.), as of Mar 25, the value is -8.45. This value is below the healthy minimum of 2. It has decreased from 10.52 (Mar 24) to -8.45, marking a decrease of 18.97.
  • For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -7.99. This value is below the healthy minimum of 2. It has decreased from 10.68 (Mar 24) to -7.99, marking a decrease of 18.67.
  • For PBDIT Margin (%), as of Mar 25, the value is 6.28. This value is below the healthy minimum of 10. It has decreased from 13.98 (Mar 24) to 6.28, marking a decrease of 7.70.
  • For PBIT Margin (%), as of Mar 25, the value is -0.54. This value is below the healthy minimum of 10. It has decreased from 8.93 (Mar 24) to -0.54, marking a decrease of 9.47.
  • For PBT Margin (%), as of Mar 25, the value is -4.46. This value is below the healthy minimum of 10. It has decreased from 7.47 (Mar 24) to -4.46, marking a decrease of 11.93.
  • For Net Profit Margin (%), as of Mar 25, the value is -4.68. This value is below the healthy minimum of 5. It has decreased from 5.33 (Mar 24) to -4.68, marking a decrease of 10.01.
  • For NP After MI And SOA Margin (%), as of Mar 25, the value is -4.42. This value is below the healthy minimum of 8. It has decreased from 5.41 (Mar 24) to -4.42, marking a decrease of 9.83.
  • For Return on Networth / Equity (%), as of Mar 25, the value is -7.21. This value is below the healthy minimum of 15. It has decreased from 8.87 (Mar 24) to -7.21, marking a decrease of 16.08.
  • For Return on Capital Employeed (%), as of Mar 25, the value is -0.56. This value is below the healthy minimum of 10. It has decreased from 10.59 (Mar 24) to -0.56, marking a decrease of 11.15.
  • For Return On Assets (%), as of Mar 25, the value is -3.03. This value is below the healthy minimum of 5. It has decreased from 4.59 (Mar 24) to -3.03, marking a decrease of 7.62.
  • For Long Term Debt / Equity (X), as of Mar 25, the value is 0.52. This value is within the healthy range. It has increased from 0.31 (Mar 24) to 0.52, marking an increase of 0.21.
  • For Total Debt / Equity (X), as of Mar 25, the value is 0.95. This value is within the healthy range. It has increased from 0.59 (Mar 24) to 0.95, marking an increase of 0.36.
  • For Asset Turnover Ratio (%), as of Mar 25, the value is 0.72. It has decreased from 0.95 (Mar 24) to 0.72, marking a decrease of 0.23.
  • For Current Ratio (X), as of Mar 25, the value is 1.24. This value is below the healthy minimum of 1.5. It has decreased from 1.56 (Mar 24) to 1.24, marking a decrease of 0.32.
  • For Quick Ratio (X), as of Mar 25, the value is 0.72. This value is below the healthy minimum of 1. It has decreased from 0.98 (Mar 24) to 0.72, marking a decrease of 0.26.
  • For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.31. This value is within the healthy range. It has increased from 1.43 (Mar 24) to 4.31, marking an increase of 2.88.
  • For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is -18.75. This value is below the healthy minimum of 20. It has decreased from 21.05 (Mar 24) to -18.75, marking a decrease of 39.80.
  • For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 34.47. This value is within the healthy range. It has increased from 10.89 (Mar 24) to 34.47, marking an increase of 23.58.
  • For Earning Retention Ratio (%), as of Mar 25, the value is 118.75. This value exceeds the healthy maximum of 70. It has increased from 78.95 (Mar 24) to 118.75, marking an increase of 39.80.
  • For Cash Earning Retention Ratio (%), as of Mar 25, the value is 65.53. This value is within the healthy range. It has decreased from 89.11 (Mar 24) to 65.53, marking a decrease of 23.58.
  • For Interest Coverage Ratio (X), as of Mar 25, the value is 1.58. This value is below the healthy minimum of 3. It has decreased from 6.68 (Mar 24) to 1.58, marking a decrease of 5.10.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -0.19. This value is below the healthy minimum of 3. It has decreased from 3.25 (Mar 24) to -0.19, marking a decrease of 3.44.
  • For Enterprise Value (Cr.), as of Mar 25, the value is 3,109.49. It has decreased from 3,659.62 (Mar 24) to 3,109.49, marking a decrease of 550.13.
  • For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.87. This value is within the healthy range. It has decreased from 2.01 (Mar 24) to 1.87, marking a decrease of 0.14.
  • For EV / EBITDA (X), as of Mar 25, the value is 29.70. This value exceeds the healthy maximum of 15. It has increased from 14.40 (Mar 24) to 29.70, marking an increase of 15.30.
  • For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.29. This value is within the healthy range. It has decreased from 1.67 (Mar 24) to 1.29, marking a decrease of 0.38.
  • For Retention Ratios (%), as of Mar 25, the value is 118.75. This value exceeds the healthy maximum of 70. It has increased from 78.94 (Mar 24) to 118.75, marking an increase of 39.81.
  • For Price / BV (X), as of Mar 25, the value is 2.11. This value is within the healthy range. It has decreased from 2.73 (Mar 24) to 2.11, marking a decrease of 0.62.
  • For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.29. This value is within the healthy range. It has decreased from 1.67 (Mar 24) to 1.29, marking a decrease of 0.38.
  • For EarningsYield, as of Mar 25, the value is -0.03. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to -0.03, marking a decrease of 0.06.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Indoco Remedies Ltd as of March 6, 2026 is: ₹89.38

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 6, 2026, Indoco Remedies Ltd is Overvalued by 54.86% compared to the current share price ₹198.00

Default values used*: Default value of 15 for Stock P/E is used

Intrinsic Value of Indoco Remedies Ltd as of March 6, 2026 is: ₹45.23

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 6, 2026, Indoco Remedies Ltd is Overvalued by 77.16% compared to the current share price ₹198.00

Default values used*: Default value of 15 for Stock P/E is used

Last 5 Year EPS CAGR: -49.40%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The company has higher reserves (753.31 cr) compared to borrowings (382.38 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (197.15 cr) and profit (72.08 cr) over the years.
  1. The stock has a low average ROCE of 12.25%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 48.33, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 151.75, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Indoco Remedies Ltd:
    1. Net Profit Margin: -4.68%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: -0.56% (Industry Average ROCE: 16.35%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: -7.21% (Industry Average ROE: 15.16%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): -0.19
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 0.72
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 0 (Industry average Stock P/E: 55.34)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.95
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Indoco Remedies Ltd. is a Public Limited Listed company incorporated on 23/08/1947 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L85190MH1947PLC005913 and registration number is 005913. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 1518.19 Cr. and Equity Capital is Rs. 18.45 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsIndoco House, 166, CST Road, Kalina, Mumbai Maharashtra 400098Contact not found
Management
NamePosition Held
Mr. Suresh G KareChairman
Ms. Aditi PanandikarManaging Director
Mr. Sundeep V BambolkarJoint Managing Director
Dr. Anand NadkarniNon Executive Director
Mr. Satish ShenoyIndependent Director
Mr. Ajay MulgaokarIndependent Director
Dr.(Ms.) Vasudha V KamatIndependent Director
Mr. Abhijit Y GoreIndependent Director

FAQ

What is the intrinsic value of Indoco Remedies Ltd?

Indoco Remedies Ltd's intrinsic value (as of 06 March 2026) is ₹45.23 which is 77.16% lower the current market price of ₹198.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,811 Cr. market cap, FY2025-2026 high/low of ₹350/194, reserves of ₹961 Cr, and liabilities of ₹2,508 Cr.

What is the Market Cap of Indoco Remedies Ltd?

The Market Cap of Indoco Remedies Ltd is 1,811 Cr..

What is the current Stock Price of Indoco Remedies Ltd as on 06 March 2026?

The current stock price of Indoco Remedies Ltd as on 06 March 2026 is ₹198.

What is the High / Low of Indoco Remedies Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Indoco Remedies Ltd stocks is ₹350/194.

What is the Stock P/E of Indoco Remedies Ltd?

The Stock P/E of Indoco Remedies Ltd is .

What is the Book Value of Indoco Remedies Ltd?

The Book Value of Indoco Remedies Ltd is 106.

What is the Dividend Yield of Indoco Remedies Ltd?

The Dividend Yield of Indoco Remedies Ltd is 0.10 %.

What is the ROCE of Indoco Remedies Ltd?

The ROCE of Indoco Remedies Ltd is 0.49 %.

What is the ROE of Indoco Remedies Ltd?

The ROE of Indoco Remedies Ltd is 7.02 %.

What is the Face Value of Indoco Remedies Ltd?

The Face Value of Indoco Remedies Ltd is 2.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Indoco Remedies Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports